Study summary
An antibody that blocks APRIL halved protein in the urine
51.2%lower urine protein than placebo at 9 months
What was tested
Sibeprenlimab, an injection that blocks APRIL, a signal that drives production of the faulty IgA antibody behind the disease, against placebo.
What they found
- Urine protein fell 50.2% vs a 2.1% rise with placebo (51.2% lower).
- Faulty galactose-deficient IgA1 fell 67.1%.
- Serious side effects were similar to placebo.
What it means
Targets the root cause of the disease rather than only protecting the kidney.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.